Computed tomography analysis of the association between the SH2B1 rs7498665 single-nucleotide polymorphism and visceral fat area. by Hotta, Kikuko et al.
Title
Computed tomography analysis of the association between the
SH2B1 rs7498665 single-nucleotide polymorphism and
visceral fat area.
Author(s)
Hotta, Kikuko; Kitamoto, Takuya; Kitamoto, Aya; Mizusawa,
Seiho; Matsuo, Tomoaki; Nakata, Yoshio; Hyogo, Hideyuki;
Ochi, Hidenori; Kamohara, Seika; Miyatake, Nobuyuki;
Kotani, Kazuaki; Komatsu, Ryoya; Itoh, Naoto; Mineo, Ikuo;
Wada, Jun; Yoneda, Masato; Nakajima, Atsushi; Funahashi,
Tohru; Miyazaki, Shigeru; Tokunaga, Katsuto; Masuzaki,
Hiroaki; Ueno, Takato; Chayama, Kazuaki; Hamaguchi,
Kazuyuki; Yamada, Kentaro; Hanafusa, Toshiaki; Oikawa,
Shinichi; Yoshimatsu, Hironobu; Sakata, Toshiie; Tanaka,
Kiyoji; Matsuzawa, Yuji; Nakao, Kazuwa; Sekine, Akihiro
CitationJ urnal of human genetics (2011), 56(10): 716-719
Issue Date2011-10
URL http://hdl.handle.net/2433/189864






Computed tomography analysis of the association between the SH2B1 rs7498665 single 
nucleotide polymorphism and visceral fat area 
 
Kikuko Hotta1, Takuya Kitamoto1, Aya Kitamoto1, Seiho Mizusawa2, Tomoaki Matsuo3, Yoshio 
Nakata3, Hideyuki Hyogo4, Hidenori Ochi4, Seika Kamohara5, Nobuyuki Miyatake6, Kazuaki 
Kotani7, Ryoya Komatsu8, Naoto Itoh9, Ikuo Mineo10, Jun Wada11, Masato Yoneda12, Atsushi 
Nakajima12, Tohru Funahashi13, Shigeru Miyazaki14, Katsuto Tokunaga15, Hiroaki Masuzaki16, 
Takato Ueno17, Kazuaki Chayama4, Kazuyuki Hamaguchi18, Kentaro Yamada19, Toshiaki 
Hanafusa20, Shinichi Oikawa21, Hironobu Yoshimatsu22, Toshiie Sakata22, Kiyoji Tanaka3, Yuji 
Matsuzawa7, Kazuwa Nakao1, 23 and Akihiro Sekine1, 2  
 
1EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan; 2Center 
for Genomic Medicine, Unit of Genome Informatics, Kyoto University Graduate School of 
Medicine, Kyoto, Japan; 3Graduate School of Comprehensive Human Sciences, University of 
Tsukuba, Tsukuba, Japan; 4Department of Medicine and Molecular Science, Division of Frontier 
Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, 
Hiroshima University, Hiroshima, Japan; 5Health Science University, Yamanashi, Japan; 
6Department of Hygiene, Faculty of Medicine, Kagawa University, Kagawa, Japan; 
7Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, 
Japan; 8Rinku General Medical Center, Osaka, Japan; 9Toyonaka Municipal Hospital, Osaka, 
Japan; 10Otemae Hospital, Osaka, Japan; 11Department of Medicine and Clinical Science, 
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
Okayama, Japan; 12Division of Gastroenterology, Yokohama City University Graduate School of 
Medicine, Yokohama, Japan; 13Department of Metabolism and Atherosclerosis, Graduate School 
of Medicine, Osaka University, Osaka, Japan; 14Tokyo Postal Services Agency Hospital, Tokyo, 
Japan; 15Itami City Hospital, Hyogo, Japan; 16Division of Endocrinology and Metabolism, 
Second Department of Internal Medicine, University of the Ryukyus Faculty of Medicine, 
Okinawa, Japan; 17Research Center for Innovative Cancer Therapy, Kurume University, Kurume, 
Japan; 18Department of Community Health and Gerontological Nursing, Faculty of Medicine, 
Oita University, Oita, Japan; 19Division of Endocrinology and Metabolism, Department of 
Medicine, Kurume University, Kurume, Japan; 20Department of Internal Medicine (I), Osaka 
Medical College, Osaka, Japan; 21Division of Endocrinology and Metabolism, Department of 
Medicine, Nippon Medical School, Tokyo, Japan; 22Department of Internal Medicine 1, Faculty 
2 
 
of Medicine, Oita University, Oita, Japan; 23Department of Medicine and Clinical Science, 
Kyoto University Graduate School of Medicine, Kyoto, Japan 
 
Corresponding author:  
Kikuko Hotta, M.D., Ph.D. 
Assistant Professor 
EBM Research Center, Kyoto University Graduate School of Medicine 
Yoshida-Konoecho, Sakyo-ku 











Visceral fat accumulation plays an important role in increasing morbidity and mortality rate by 
increasing the risk of developing several metabolic disorders, such as type 2 diabetes, 
dyslipidemia, and hypertension.  New genetic loci that contribute to the development of 
obesity have been identified by genome-wide association studies in Caucasian populations.  
We genotyped 1279 Japanese subjects (556 men and 723 women), who underwent computed 
tomography (CT) for measuring visceral fat area (VFA) and subcutaneous fat area (SFA), for the 
following single nucleotide polymorphisms (SNPs): NEGR1 rs2815752, SEC16B rs10913469, 
TMEM18 rs6548238, ETV5 rs7647305, GNPDA2 rs10938397, BDNF rs6265 and rs925946, 
MTCH2 rs10838738, SH2B1 rs7498665, MAF rs1424233, and KCTD15 rs29941 and 
rs11084753.  In the additive model, none of the SNPs were significantly associated with BMI.  
The SH2B1 rs7498665 risk allele was found to be significantly associated with VFA (P = 
0.00047) but not with BMI or SFA.  When the analysis was performed in men and women 
separately, no significant associations with VFA were observed (P = 0.0099 in men and P = 
0.022 in women).  None of the other SNPs were significantly associated with SFA.  Our 
results suggest that there is a VFA-specific genetic factor and that a polymorphism in the SH2B1 










Obesity, especially visceral fat obesity, is a risk factor for several metabolic disorders, including 
type 2 diabetes, dyslipidemia, and hypertension.1  Several studies have indicated that adipose 
tissue, especially that in the visceral region, secretes various adipocytokines and that an increase 
in adipose tissue mass leads to alteration in the plasma levels of adipocytokines, resulting in the 
development of dyslipidemia, hypertension, and insulin resistance.2, 3  Intra-abdominal fat 
accumulation (central adiposity) is determined in terms of waist circumference; waist-hip ratio; 
or visceral fat area (VFA), which is measured using computed tomography (CT).1, 4, 5  Recently, 
2 genome-wide association studies (GWASs) were conducted to identify the loci linked with 
waist circumference and waist-hip ratio.6, 7  In a previous study, we have reported that the 
rs1558902 and rs1421085 genotypes of the fat mass and obesity associated gene (FTO) were 
significantly associated with VFA as well as with subcutaneous fat area (SFA) and body mass 
index (BMI).8 
We performed a large-scale, case-control association study and found that 
secretogranin III (SCG3)9 and myotubularin-related protein 9 (MTMR9)10 conferred 
susceptibility to an obese phenotype in the Japanese population.  Recent progress in GWASs 
has increased the number of known genetic susceptibility loci for obesity.11-13  Some of the 
obesity-associated loci identified by the GWAS were found to be replicated in the Japanese 
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population.14,15  Some of the obesity-related loci were found to overlap with the waist 
circumference- waist-hip ratio-related loci, for example, the loci within the FTO gene and near 
the melanocortin 4 receptor (MC4R) gene. 
In this study, we investigated whether the recently reported obesity-related loci were 
associated with VFA, which is an important factor responsible for increased morbidity and 
mortality rates. 
 
MATERIALS AND METHODS 
Study subjects 
In this study, we enrolled 1279 Japanese subjects from outpatient clinics; these patients had 
agreed to undergo CT testing (in the supine position) to determine the VFA and SFA values at 
the umbilical level (L4–L5).  Both VFA and SFA values were calculated using the FatScan 
software program (N2system, Osaka, Japan).16  The patients visited the hospitals to undergo 
the treatment for obesity and/or metabolic abnormalities such as hypertension, dyslipidemia, 
and type 2 diabetes.  Patients with secondary obesity and obesity-related hereditary disorders 
were excluded from this study.  Patients with disease or under treatment that strongly affect the 
body weight were also excluded.  The clinical data were taken at the first visit to the hospital.  
The clinical characteristics of the subjects are summarized in Table 1.  Metabolic syndrome 
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and metabolic abnormalities were diagnosed according to the criteria released by the Japanese 
Committee for the Diagnostic Criteria of Metabolic Syndrome in April 2005.4, 5  Written 
informed consent was obtained from each subject, and the protocol was approved by the ethics 
committee of each institution and by that of Kyoto University. 
DNA extraction and single nucleotide polymorphism genotyping 
Genomic DNA was extracted from the blood samples collected from each subject by using 
Genomix (Talent Srl, Trieste, Italy).  We selected 12 single nucleotide polymorphisms (SNPs) 
identified as susceptibility loci for obesity by GWASs in Caucasian populations11-13 and 
constructed Invader probes (Third Wave Technologies, Madison, WI, USA) for the following 
SNPs: rs2815752 in the neuronal growth regulator 1 gene (NEGR1); rs10913469 in the SEC16 
homolog B gene (SEC16B); rs6548238 in the transmembrane protein 18 gene (TMEM18); 
rs7647305 in the ets variant 5 gene (ETV5); rs10938397 in the glucosamine-6-phosphate 
deaminase 2 gene (GNPDA2); rs6265 and rs925946 in the brain-derived neurotrophic factor 
gene (BDNF); rs10838738 in the mitochondrial carrier homolog 2 gene (MTCH2); rs7498665 in 
the SH2B adaptor protein 1 gene (SH2B1); rs1424233 in the v-maf musculo-aponeurotic 
fibrosarcoma oncogene homolog gene (MAF); and rs29941 and rs11084753 in the potassium 
channel tetramerisation domain containing 15 gene (KCTD15).  The SNPs were genotyped 




For the additive model, we coded the genotypes as 0, 1, or 2 depending on the number of copies 
of the risk alleles.  For the dominant model, homozygosity and heterozygosity with the risk 
allele were coded as 1 and the other was coded as 0.  Multiple linear regression analyses were 
performed to test the independent effect of the risk alleles on BMI, VFA, and SFA by taking into 
account the effects of other variables (i.e., age and gender) that were assumed to be independent 
of the effect of each SNP.  The Hardy–Weinberg equilibrium was assessed using the χ2-test.18  
Statistical analysis was performed using the software R (http://www.r-project.org/).  P–values 




The clinical characteristics and genotypes of the subjects are shown in Tables 1 and 2, 
respectively.  All the SNPs were in the Hardy–Weinberg equilibrium.  The BMI, VFA, and 
SFA values for each SNP genotype are represented in Table 3.  Multiple linear regression 
analyses of the anthropometric parameters with respect to the 12 SNPs analyzed are shown in 
Table 4.  No SNPs were not significantly associated with BMI in this population, though a 
previous study reported that the SEC16B rs109134 and TMEM18 rs6548238 SNPs were 
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significantly associated with obesity (BMI > 30 kg m-2) in the Japanese population.15 
The SH2B1 rs7498665 SNP was significantly associated with VFA (P = 0.00047) even 
when the conservative Bonferroni’s correction was applied (P < 0.0042).  Previous reports 
indicate that the rs7498665 SNP is associated with waist circumference19 or visceral fat mass20 
in the dominant model.  The VFA values of the rs7498665 genotype (Table 3) suggest that the 
dominant model would be best fitted model.  Therefore, we performed multiple regression 
analyses by using the dominant model and found a significant association between this SNP and 
VFA (P = 0.00022).  This association remained significant even after adjusting for age, gender, 
and BMI in the dominant model (P = 0.00096).  The other SNPs did not show any significant 
association with VFA.  No SNPs, including the SH2B1 rs7498665, were associated with SFA. 
BMI, VFA and SFA are known to be affected by gender; therefore, we compared the 
anthropometric parameters (BMI, VFA and SFA) among the different genotypes in the men and 
women (Supplementary Table 1, 2 and 3).  Association between SH2B1 rs7498665 SNP and 
VFA was not significant both in men (P = 0.0099) and women (P = 0.022).  This negative 
association is most likely due to the decrease in the number of each genotype.  The VFA values 
of the rs7498665 genotype (Supplementary Table 2) suggest that the dominant model would be 
best fitted model both in men and women.  By using the dominant model revealed no 
significant association between the rs7498665 genotype and VFA in men (P = 0.0061) and 
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women (P = 0.015). 
To confirm the association of the SH2B1 rs7498665 SNP with VFA, 2 SNPs 
(rs4788102 and rs8049439) in linkage disequilibrium of rs7498665 reported by previous study11 
were genotyped (Supplementary Table 4).  Both rs4788102 (P = 0.00058) and rs8049439 (P = 
0.0021) SNPs were significantly associated with VFA. 
 
DISCUSSION 
In this study, we showed that the SH2B1 rs7498665 SNP was significantly associated with VFA.  
Haupt et al. used whole-body magnetic resonance imaging (MRI) to show that this SNP 
(dominant model) was associated with visceral fat mass.20  They also reported that the SH2B1 
rs7498665 SNP was not associated with BMI or with nonvisceral fat mass.  Jamshidi et al. 
reported that the SH2B1 rs7498665 SNP (dominant model) was associated with waist 
circumference.19  Several studies have reported a negative association between the SH2B1 
rs7498665 SNP and abdominal adipose mass (measured using dual energy X-ray absorptiometry 
[DEXA])21 or waist circumference.22, 23  CT- or MRI-based analyses are more accurate than 
waist circumference- and DEXA-based abdominal fat mass analysis for evaluating the 
association between this SNP and visceral fat mass.  The data from this study and from the 
study performed by Haupt et al. strongly suggest that the SH2B1 rs7498665 SNP is associated 
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with visceral fat accumulation. 
 SH2B1 has 4 splicing isoforms, i.e., α, , γ, and δ, of which SH2-B was originally 
identified through its association with Janus kinase 2 (JAK2) protein, a cytoplasmic tyrosine 
kinease that mediates cytokine actions.24  SH2B1-knockout mice have been reported to show 
severely impaired insulin signaling in the skeletal muscles, liver, and adipose tissue and 
progressively develop hyperinsulinemia, hyperglycemia, and glucose intolerance.25  
SH2B1-knockout mice also developed hyperlipidemia, leptin resistance, hyperphagia, and 
obesity.26  Although data for mesenteric fat has not been reported, both subcutaneous inguinal 
fat and intra-abdominal (epididymal) fat were found to be increased in SH2B1-knockout mice.26, 
27  Neuron-specific restoration of SH2B1 in knockout mice corrected the metabolic disorders, 
improved leptin regulation of orexigenic neuropeptide expression in the hypothalamus, and 
protected against high-fat diet-induced leptin resistance and obesity.27  Ventromedial 
hypothalamic (VMH) lesions are reported to induce visceral fat accumulation that does not 
result in obesity, and to induce hyperglycemia, hyperinsulinemia, and hypertriglyceridemia.28  
SH2B1 was specifically expressed in the brain, including the hypothalamus, in mice with 
neuron-specific SH2B1 restoration.27  Therefore, SH2B1 expression in hypothalamus (possibly 
the VMH) may play an important role in visceral fat accumulation.  Since the SH2B1 
rs7498665 SNP is a non-synonymous SNP (G/A, Ala484Thr) and exits in the proline-rich region, 
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the function of the SH2B1 protein might be deteriorated in subjects with the risk G-allele, 
leading to visceral fat accumulation.  The rs4788102 SNP exists in the 5′-flanking region of the 
SH2B1 gene, thus, the expression of SH2B1 may be changed in the subjects with the risk 
A-allele.  It is necessary to investigate whether these SNPs are functional. 
 In summary, we showed that the SH2B1 rs7498665 SNP is significantly associated 
with VFA.  This SNP is not associated with BMI or SFA, suggesting that there is a 
VFA-specific genetic factor.  Our results also suggest that the SH2B1 gene plays a role in 
visceral fat accumulation.  However, these results need to be confirmed in other populations. 
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Table 1  Clinical characteristics of the subjects 
 Men Women Total 
n 556 723 1279 
Age (years) 49.4 ± 12.2 52.2 ± 11.3 51.0 ± 11.8 
BMI (kg m-2) 30.2 ± 6.1 28.1 ± 5.3 29.0 ± 5.8 
VFA (cm2) 155.3 ± 67.7 99.8 ± 53.6 123.9 ± 66.1 
SFA (cm2) 206.7 ± 108.6 241.6 ± 97.2 226.5 ± 103.7 
Waist circumference (cm) 97.5 ± 11.3 91.8 ± 10.3 94.2 ± 11.1 
    
Prevalence of metabolic disease    
  Dyslipidemia 293 (53%) 244 (34%) 537 (42%) 
  Hypertension 379 (68%) 452 (63%) 831 (65%) 
  Impaired fasting glucose 177 (32%) 176 (24%) 353 (28%) 
  Metabolic syndrome 248 (45%) 162 (22%) 410 (32%) 
Data are shown as mean ± s.d. 
Table 2  Genotypic characteristics of the subjects 








rs2815752 NEGR1 A/G A 1113/163/3 0.24 
rs10913469 SEC16B T/C C 690/510/78 0.20 
rs6548238 TMEM18 T/C C 6/201/1071 0.29 
rs7647305 ETV5 C/T C 201/576/500 0.10 




G 207/609/462 0.79 
rs925946 BDNF T/G T 3/100/1175 0.57 




G 29/305/945 0.46 
rs1424233 MAF C/G C 726/469/82 0.59 
rs29941 KCTD15 T/C C 774/444/60 0.72 
rs11084753 KCTD15 G/A G 105/535/638 0.63 
HWE, Hardy-Weinberg equilibrium. 
Table 3  Mean BMI, VFA, and SFA for 12 obesity-risk variants 
   Mean ± SD  
 Nearby BMI (kg m-2) VFA (cm2) SFA (cm2) 
SNP ID gene 11 12 22 11 12 22 11 12 22 
rs2815752 NEGR1 29.1 ± 5.9 28.3 ± 5.3 28.5 ± 3.1 124.8 ± 66.7 118.5 ± 62.6 95.2 ± 38.8 226.1 ± 103.1 228.3 ± 108.5 251.0 ± 79.8 
rs10913469 SEC16B 28.8 ± 5.9 29.2 ± 5.6 29.7 ± 6.5 123.0 ± 66.4 124.9 ± 65.2 124.8 ± 70.4 221.7 ± 103.7 231.6 ± 102.6 234.0 ± 110.5 
rs6548238 TMEM18 25.9 ± 7.5 29.0 ± 7.2 29.0 ± 5.5 85.9 ± 70.6 123.4 ± 67.1 124.3 ± 65.9 211.0 ± 135.0 222.8 ± 111.3 227.3 ± 102.2 
rs7647305 ETV5 29.0 ± 5.3 29.1 ± 5.4 29.0 ± 6.3 124.5 ± 66.8 124.5 ± 66.3 123.2 ± 65.8 234.1 ± 99.5 225.6 ± 100.0 224.6 ± 109.6 
rs10938397 GNPDA2 28.8 ± 5.9 29.1 ± 5.8 29.2 ± 5.3 122.7 ± 68.0 124.5 ± 64.0 127.4 ± 66.3 224.5 ± 103.4 227.9 ± 103.3 229.3 ± 107.5 
rs6265 BDNF 28.6 ± 5.9 28.7 ± 5.3 29.6 ± 6.3 122.4 ± 68.2 122.9 ± 64.7 126.1 ± 67.1 220.3 ± 92.9 223.5 ± 102.2 233.2 ± 109.9 
rs925946 BDNF 36.0 ± 10.7 29.5 ± 6.1 28.9 ± 5.7 142.6 ± 11.3 123.3 ± 63.3 124.0 ± 66.4 416.8 ± 155.7 236.3 ± 118.6 225.2 ± 101.9 
rs10838738 MTCH2 28.7 ± 4.9 29.3 ± 6.4 28.7 ± 5.3 124.5 ± 58.3 125.1 ± 68.5 122.6 ± 65.2 214.1 ± 93.1 233.6 ± 109.6 222.2 ± 99.8 
rs7498665 SH2B1 29.7 ± 4.8 29.5 ± 6.2 28.8 ± 5.7 134.4 ± 65.3 134.5 ± 70.5 120.2 ± 64.3 231.1 ± 95.9 235.1 ± 98.4 223.6 ± 105.5 
rs1424233 MAF 29.0 ± 6.0 29.1 ± 5.7 28.4 ± 3.8 123.1 ± 64.7 124.0 ± 65.7 130.6 ± 80.4 222.0 ± 102.6 234.0 ± 109.1 219.7 ± 74.5 
rs29941 KCTD15 28.8 ± 5.6 29.1 ± 6.0 30.4 ± 6.0 123.9 ± 65.2 122.4 ± 67.3 136.5 ± 68.5 224.8 ± 103.7 228.2 ± 103.5 236.6 ± 106.6 
rs11084753 KCTD15 29.5 ± 5.7 29.1 ± 5.8 28.9 ± 5.8 128.3 ± 71.9 122.5 ± 64.9 124.5 ± 66.2 233.0 ± 98.6 227.4 ± 102.0 224.7 ± 106.1 
11, allele1/allele1; 12, allele1/allele2; 22, allele2/allele2.  Allele1 and allele2 in each SNP is indicated in Table2. 
Table 4  Relationship between obesity loci and adiposity measures 
 Nearby  BMI   VFA   SFA  
SNP ID gene  SE P-value  SE P-value  SE P-value 
rs2815752 NEGR1 0.611 0.448 0.17 7.423 4.847 0.13 -6.293 7.978 0.43 
rs10913469 SEC16B 0.325 0.255 0.20 2.827 2.753 0.30 4.516 4.532 0.32 
rs6548238 TMEM18 0.267 0.403 0.51 6.773 4.352 0.12 2.557 7.178 0.72 
rs7647305 ETV5 0.025 0.221 0.91 1.984 2.386 0.41 2.565 3.929 0.51 
rs10938397 GNPDA2 0.199 0.236 0.40 0.804 2.547 0.75 4.065 4.190 0.33 
rs6265 BDNF 0.508 0.223 0.023 1.390 2.410 0.56 6.954 3.968 0.080 
rs925946 BDNF 0.816 0.545 0.14 0.390 5.897 0.95 18.972 9.685 0.050 
rs10838738 MTCH2 0.162 0.243 0.51 0.292 2.628 0.91 2.726 4.326 0.53 
rs7498665 SH2B1 0.536 0.310 0.085 11.717 3.343 0.00047 8.341 5.555 0.13 
rs1424233 MAF 0.050 0.252 0.84 -2.945 2.722 0.28 -5.311 4.479 0.24 
rs29941 KCTD15 0.481 0.265 0.070 2.588 2.871 0.37 3.589 4.727 0.45 
rs11084753 KCTD15 0.332 0.243 0.17 1.562 2.626 0.55 3.242 4.322 0.45 
Data were derived from a linear regression analysis.  BMI, VFA, and SFA were adjusted for age and gender. 
Supplementary Table 1  Genotypic characteristics of the subjects in men and women 
    Men Women 
SNP ID Nearby gene Allele1/2 Risk allele Genotype HWE P-value Genotype HWE P-value 
rs2815752 NEGR1 A/G A 484/71/1 0.33 629/92/2 0.48 
rs10913469 SEC16B T/C C 307/215/34 0.65 383/295/44 0.19 
rs6548238 TMEM18 T/C C 2/101/453 0.14 4/100/618 0.98 
rs7647305 ETV5 T/C C 81/252/222 0.49 120/324/278 0.12 
rs10938397 GNPDA2 A/G G 257/241/57 0.96 358/296/69 0.49 
rs6265 BDNF A/G G 88/259/209 0.60 119/350/253 0.91 
rs925946 BDNF T/G T 0/47/509 0.30 3/53/666 0.09 
rs10838738 MTCH2 G/A G 51/246/258 0.48 56/309/358 0.34 
rs7498665 SH2B1 G/A G 13/135/408 0.65 16/170/537 0.56 
rs1424233 MAF A/G A 321/200/35 0.61 405/269/47 0.80 
rs29941 KCTD15 T/C C 341/190/25 0.82 433/254/35 0.77 
rs11084753 KCTD15 G/A G 44/222/290 0.87 61/313/348 0.42 
HWE, Hardy-Weinberg equilibrium. 
Supplementary Table 2  Mean BMI, VFA, and SFA for 12 obesity-risk variants in men and women 
    Mean ± SD  
 Nearby  BMI (kg m-2) VFA (cm2) SFA (cm2) 
SNP ID gene Gender 11 12 22 11 12 22 11 12 22 
rs2815752 NEGR1 Men 30.3 ± 6.2 29.5 ± 5.8 30.4 156.4 ± 67.9 148.9 ± 66.2 78.5 206.2 ± 107.3 210.8 ± 118.2 173.8 
  Women 28.2 ± 5.4 27.3 ± 4.7 27.6 ± 3.7 100.4 ± 54.4 95.1 ± 48.3 103.6 ± 50.8 241.5 ± 97.1 241.7 ± 99.0 289.6 ± 61.5 
rs10913469 SEC16B Men 30.0 ± 6.5 30.3 ± 5.6 31.2 ± 5.4 154.4 ± 69.4 156.9 ± 63.8 153.5 ± 77.3 202.2 ± 107.8 211.7 ± 110.9 216.5 ± 102.0 
  Women 27.8 ± 5.1 28.4 ± 5.4 28.6 ± 7.1 97.8 ± 51.7 101.6 ± 55.6 102.5 ± 56.0 237.4 ± 97.7 246.1 ± 93.6 247.5 ± 116.0 
rs6548238 TMEM18 Men 31.2 ± 11.6 30.4 ± 8.8 30.1 ± 5.4 122.2 ± 114.3 149.5 ± 70.4 156.8 ± 67.0 274.2 ± 237.3 207.1 ± 125.6 206.4 ± 104.2 
  Women 23.3 ± 4.6 27.7 ± 4.7 28.2 ± 5.4 67.8 ± 51.4 97.0 ± 51.9 100.5 ± 53.9 179.4 ± 87.4 238.5 ± 92.8 242.7 ± 97.9 
rs7647305 ETV5 Men 30.4 ± 5.2 30.3 ± 5.8 29.9 ± 6.8 156.8 ± 67.3 155.2 ± 68.2 155.1 ± 67.7 223.4 ± 112.4 204.9 ± 107.7 202.9 ± 108.3 
  Women 28.0 ± 5.2 28.1 ± 4.9 28.2 ± 5.9 102.8 ± 57.1 100.6 ± 53.9 97.7 ± 51.7 241.3 ± 89.6 241.6 ± 90.6 242.1 ± 107.6 
rs10938397 GNPDA2 Men 30.0 ± 6.5 30.4 ± 6.1 30.1 ± 4.4 155.0 ± 71.5 156.0 ± 63.4 154.5 ± 69.6 201.9 ± 111.0 210.0 ± 106.0 213.2 ± 109.7 
  Women 28.0 ± 5.2 28.1 ± 5.4 28.4 ± 5.8 99.5 ± 54.7 98.9 ± 52.1 105.0 ± 54.5 240.6 ± 94.6 242.6 ± 98.9 242.7 ± 104.6 
rs6265 BDNF Men 29.8 ± 5.9 29.9 ± 5.9 30.6 ± 6.5 156.9 ± 62.2 152.3 ± 68.0 158.5 ± 69.7 201.7 ± 94.8 200.8 ± 109.7 216.3 ± 112.3 
  Women 27.7 ± 5.7 27.8 ± 4.7 28.7 ± 5.9 96.9 ± 61.0 101.2 ± 52.6 99.3 ± 51.4 234.1 ± 89.5 240.4 ± 92.9 247.2 ± 106.1 
rs925946 BDNF Men – 31.4 ± 5.9 30.0 ± 6.1 – 156.3 ± 59.6 155.2 ± 68.5 – 233.9 ± 119.0 204.2 ± 107.4 
  Women 36.0 ± 10.7 27.9 ± 5.9 28.1 ± 5.2 142.6 ± 11.3 94.1 ± 51.2 100.1 ± 53.8 416.8 ± 155.7 238.5 ± 119.4 241.2 ± 94.4 
rs10838738 MTCH2 Men 29.6 ± 5.4 30.4 ± 7.0 30.0 ± 5.4 144.4 ± 63.4 159.0 ± 71.1 153.8 ± 65.1 178.9 ± 87.1 213.0 ± 111.4 206.3 ± 109.4 
  Women 28.0 ± 4.4 28.5 ± 5.9 27.8 ± 5.0 106.4 ± 46.7 98.2 ± 52.6 100.1 ± 55.4 246.2 ± 87.1 250.1 ± 105.4 233.6 ± 90.7 
rs7498665 SH2B1 Men 31.3 ± 5.4 30.9 ± 7.2 29.9 ± 5.7 165.9 ± 73.5 168.5 ± 69.5 150.6 ± 66.5 213.7 ± 120.9 222.6 ± 104.6 201.3 ± 109.3 
  Women 28.3 ± 3.9 28.4 ± 5.1 28.0 ± 5.5 108.7 ± 45.6 107.6 ± 58.9 97.0 ± 51.8 246.2 ± 68.5 244.9 ± 92.3 240.5 ± 99.5 
rs1424233 MAF Men 30.2 ± 6.9 30.3 ± 5.1 29.0 ± 3.7 153.5 ± 65.7 156.3 ± 65.2 167.2 ± 95.3 203.2 ± 111.5 215.2 ± 109.6 191.4 ± 65.8 
  Women 28.0 ± 5.0 28.3 ± 6.0 27.9 ± 3.8 98.9 ± 52.7 99.9 ± 54.9 103.4 ± 53.8 236.9 ± 92.4 248.1 ± 106.8 240.7 ± 74.2 
rs29941 KCTD15 Men 30.0 ± 5.8 30.5 ± 6.8 29.9 ± 4.7 154.3 ± 65.7 156.1 ± 70.5 164.3 ± 74.4 204.3 ± 106.7 211.6 ± 114.1 203.3 ± 92.0 
  Women 27.9 ± 5.2 28.1 ± 5.2 30.7 ± 6.8 100.1 ± 54.0 97.1 ± 52.1 116.7 ± 57.1 240.9 ± 98.4 240.6 ± 93.1 260.3 ± 111.0 
rs11084753 KCTD15 Men 29.5 ± 5.1 30.3 ± 6.4 30.1 ± 6.0 158.9 ± 81.5 153.5 ± 66.3 156.2 ± 66.7 207.7 ± 100.0 207.7 ± 109.7 205.8 ± 109.4 
  Women 29.5 ± 6.2 28.2 ± 5.1 27.8 ± 5.4 106.2 ± 54.9 100.5 ± 54.0 98.1 ± 53.0 251.3 ± 94.3 241.3 ± 93.9 240.5 ± 100.7 
11, allele1/allele1; 12, allele1/allele2; 22, allele2/allele2.  Allele1 and allele2 in each SNP is indicated in Supplementary Table1. 
Supplementary Table 3  Relationship between obesity loci and adiposity measures in men and women 
 Nearby   BMI   VFA   SFA  
SNP ID gene Gender  SE P-value  SE P-value  SE P-value 
rs2815752 NEGR1 Men 0.412 0.724 0.57 9.582 8.386 0.25 -8.762 12.782 0.49 
  Women 0.746 0.564 0.19 5.661 5.653 0.32 -4.606 10.135 0.65 
rs10913469 SEC16B Men 0.360 0.407 0.38 1.132 4.716 0.81 6.421 7.182 0.37 
  Women 0.338 0.323 0.30 4.531 3.236 0.16 3.451 5.810 0.55 
rs6548238 TMEM18 Men -0.322 0.619 0.60 8.070 7.173 0.26 -2.593 10.976 0.81 
  Women 0.811 0.526 0.12 5.788 5.280 0.27 7.388 9.469 0.44 
rs7647305 ETV5 Men 0.174 0.358 0.63 0.740 4.154 0.86 6.997 6.322 0.27 
  Women -0.090 0.276 0.75 2.832 2.768 0.31 -0.768 4.972 0.88 
rs10938397 GNPDA2 Men 0.188 0.376 0.62 0.186 4.363 0.97 6.480 6.645 0.33 
  Women 0.192 0.299 0.52 1.141 2.993 0.70 2.063 5.364 0.70 
rs6265 BDNF Men 0.490 0.355 0.17 1.927 4.121 0.64 9.648 6.281 0.13 
  Women 0.553 0.283 0.051 1.257 2.836 0.66 5.199 5.091 0.31 
rs925946 BDNF Men 1.156 0.891 0.20 1.254 10.343 0.90 26.135 15.711 0.097 
  Women 0.554 0.678 0.42 -0.411 6.807 0.95 13.655 12.190 0.26 
rs10838738 MTCH2 Men -0.022 0.385 0.95 -0.774 4.456 0.86 -6.099 6.790 0.37 
  Women 0.317 0.311 0.31 1.239 3.113 0.69 9.960 5.571 0.074 
rs7498665 SH2B1 Men 0.761 0.493 0.12 14.734 5.692 0.0099 13.960 8.717 0.11 
  Women 0.333 0.395 0.40 9.102 3.949 0.022 3.603 7.170 0.62 
rs1424233 MAF Men 0.246 0.405 0.54 -4.845 4.688 0.30 -3.566 7.148 0.62 
  Women -0.100 0.319 0.75 -1.504 3.183 0.64 -6.676 5.704 0.24 
rs29941 KCTD15 Men 0.205 0.428 0.63 3.185 4.965 0.52 3.179 7.570 0.68 
  Women 0.689 0.333 0.039 2.119 3.348 0.53 3.844 6.006 0.52 
rs11084753 KCTD15 Men -0.064 0.390 0.87 -0.483 4.520 0.92 2.266 6.885 0.74 
  Women 0.639 0.306 0.037 3.154 3.073 0.31 3.997 5.513 0.47 
Data were derived from a linear regression analysis.  BMI, VFA, and SFA were adjusted for age. 
Supplementary Table 4  Relationship between SNPs in SH2B1 loci and adiposity measures 
 Position Allele Risk  BMI VFA SFA  
SNP ID (build 36.3) 1/2 allele Genotype  (SE) P-value  (SE) P-value  (SE) P-value D′/r2 
rs8049439 28745016 C/T C 71/475/731 0.628 (0.258) 0.015 8.582 (2.781) 0.0021 7.653 (4.599) 0.096 1.00/0.51 
rs4788102 28780899 A/G A 29/304/944 0.530 (0.311) 0.088 11.546 (3.347) 0.00058 8.018 (5.561) 0.15 1.00/1.00 
rs7498665 28790742 G/A G 29/305/945 0.536 (0.310) 0.085 11.717 (3.343) 0.00047 8.341 (5.555) 0.13 – 
Data were derived from a linear regression analysis.  BMI, VFA, and SFA were adjusted for age and gender. 
